Athira pharma reports third quarter 2022 financial results and recent clinical and corporate updates

Independent, unblinded, interim efficacy and futility analysis of phase 2/3 lift-ad study in mild-to-moderate alzheimer's disease patients supports potential clinically meaningful activity of fosgonimeton without background acetylcholinesterase therapy and mitigates program risk
ATHA Ratings Summary
ATHA Quant Ranking